Efficacy of Apixaban in Malignancy With Deep Venous Thrombosis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT04462003

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04462003
Other papers using this trial's data
  • Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis Vascular, 2021-10 DOI, PubMed 33153401

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04462003. Randomized; single masking; primary purpose treatment. Start 2019-07-03 (actual); primary completion 2020-07-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Apixaban in Malignancy With Deep Venous Thrombosis
Condition
Malignancy
Intervention (Drug)
Apixaban
Intervention (Drug)
Enoxaparin
Lead sponsor
Beni-Suef University (class: other)

Record details

Record id
cardio:ct-nct04462003
Content hash
b90034c0c6b86abab1f633affe971d5711b9e2358aa8255b20d8cfe824fd2de2